Under the microscope with Dr Jeffrey A. Borgia, Rush University Medical Center
Researchers at Rush Medical Center are developing novel diagnostic tests to help guide treatment decisions for patients with non-small cell lung cancer...
List view / Grid view
Articles
Product Showcase: End-to-end next-generation sequencing for clinical diagnostics
20 September 2016 | By Vela Diagnostics
Fuelled by the rapid development of next-generation sequencing (NGS) technologies, it has become apparent that the technology is a key for the identification of genetic variants...
Flow cytometry: breaking bottlenecks in drug discovery and development
The discovery and development of novel drug candidates is a highly complex, time-consuming and expensive process. Pharmaceutical scientists and clinicians should, therefore, reevaluate and modify the existing standard platforms and increase their uptake of robust advanced technologies such as flow cytometry to overcome the bottlenecks in these processes...
Switching on genes regulating oxysterol synthesis – a therapeutic option?
Cholesterol is a ubiquitous molecule that, while essential for health, is probably best known as a risk factor for cardiovascular disease. It is also the obligate precursor for a wide range of metabolites, from steroid hormones to bile acids. Although studied for more than 100 years, recently there has been…
High-throughput calcium flux assays: luminescent versus fluorescent readout
In vitro high-throughput cellular target-based assays are commonly used for hit identification targeting G-protein coupled receptors (GPCR). Agonist and antagonist identification of GPCRs often relies on the screening of large collections of chemicals using miniaturised in vitro cell-based functional assays. In the panel of assays, calcium mobilisation measured by aequorin…
Fibromyalgia pathogenesis provides drug target clues
Fibromyalgia (FM) has been described as a condition of heightened generalised sensitisation to sensory input presenting as a complex of symptoms dominated by chronic widespread pain characterised by hyperalgesia and allodynia. A range of co-morbidities of variable intensity, such as fatigue, sleep disturbance, cognitive impairment, anxiety and depression, are often…
Practical application of in vivo optical imaging in biotherapeutic biodistribution analyses
As advances in protein engineering technology have led to the production of novel and more structurally complex biopharmaceuticals, the ability of these drugs to smoothly traverse the body and arrive at their intended target site has become more unpredictable...
A picture is worth a thousand endpoints: high-content imaging in drug discovery
Over the past few years several factors in the drug discovery industry have come together to drive an increased interest and subsequent surge in the use of high-content imaging. These include the high costs of attrition in the clinic due to lack of efficacy; increased hurdles and rising costs to…
Zebrafish early-life stages as neurological screening and detection tools
Unforeseen efficacy and safety-related issues with drugs continue to be a major cause of their attrition, despite significant efforts that are expended to eliminate them prior to initiating clinical trials...
Hit-to-lead in drug discovery
Starting in the 1970s, the drug discovery research process changed dramatically. Our understanding of biological targets and pathways grew and the largely empirical and target agnostic in vivo pharmacology approach was replaced with target-centric methods...
Cannabinoids: Medicalising marijuana for the treatment of major diseases
24 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Drug Target Review caught up with Dr Brian Murphy, CEO and Chief Medical Officer of Nemus Bioscience, to find out the latest in cannabinoid research…
Could Pokémon Go help curb the diabetes pandemic?
15 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Drug Target Review caught up with Dr Emily Burns, Research Communications Manager Diabetes UK to find out how this smartphone craze could impact the rising levels of Diabetes…
Moderna discuss mRNA therapeutics in cystic fibrosis
22 July 2016 | By Victoria White, Digital Content Producer
Drug Target Review recently caught up with Lorence Kim, Chief Financial Officer of Moderna, to find out more about the company‘s collaboration with Vertex and using mRNA therapeutics to treat patients with cystic fibrosis...
How NIH’s $30 million research fund will help find HIV cure
20 July 2016 | By Niamh Louise Marriott, Digital Content Producer
The NIH recently awarded $30 million to advance science towards a cure for HIV. Drug Target Review caught up with the Wistar Institute‘s Dr. Luis Montaner, co-leader of the BEAT-HIV project...
Lyme disease: mystery, misery and hope
15 July 2016 | By Victoria White, Digital Content Producer
Drug Target Review recently caught up with Veronica Hughes, CEO of the Caudwell Lyme Disease charity, to find out more about the disease...